CClinicalTrials.gg
Sign In
TerminatedNCT03861403Updated Nov 30, 2023

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

A Phase 1 interventional study of TRX518 and Cyclophosphamide in Solid Tumors, Advanced Triple Negative Breast Cancer and Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, sponsored by Leap Therapeutics, Inc.. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-30.

Sponsored by Leap Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Product development discontinued unrelated to safety.

From the registry’s dates

  • Primary completion was Jul 2020, 6 years 2 months ago, and no results have been posted to the registry.
Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1b/2a dose escalation and expansion, multi-center study to be conducted in 2 phases:

  • Phase 1b

    • Dose Escalation Part 1 (Doublet Therapy)
    • Dose Escalation Part 2 (Triplet Therapy)

  • Phase 2a

    • Dose Expansion (Triplet Therapy)

Approximately 125 adult patients with histologically confirmed advanced solid tumors requiring therapy will be enrolled in the study. It is expected that approximately 24 patients will be enrolled in up to 4 cohorts, 2 cohorts in Dose Escalation Part 1 and 2 cohorts in Dose Escalation Part 2, of up to 6 patients per cohort. Up to 98 additional patients will be enrolled in the Dose Expansion phase of the study to achieve 88 evaluable patients (i.e., received at least 1 dose of study drug(s) and have 1 evaluable post-baseline modified RECIST v1.1 tumor response assessment; for mCRPC, assessment of soft tissue response will be per modified RECIST v1.1 and bone progression assessment will be per PCWG3 guidelines or discontinued treatment due to death, toxicity, or clinical progression) over 4 independent expansion groups.In either phase (1b or 2a), patients discontinuing for reasons unrelated to study treatment toxicity prior to completion of Cycle (C) 1 may be replaced to achieve the number of required evaluable patients per cancer type following consultation with the Sponsor. Data from each cohort in the Dose Escalation phase will be evaluated independently for safety and dose limiting toxicities (DLTs) prior to dose escalation and again prior to the Dose Expansion phase.

02

Conditions studied

  • Solid Tumors
  • Advanced Triple Negative Breast Cancer
  • Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer
  • Advanced Metastatic Castration-Resistant Prostate Cancer
  • Advanced Platinum-Resistant Ovarian Cancer

Keywords

  • Metastatic
  • Stage III or IV
  • Recurrent
  • Refractory
  • Solid tumors
  • Breast cancer
  • Prostate cancer
  • Ovarian cancer
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 10 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Leap Therapeutics, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Advanced Solid Malignancies in Dose Escalation Parts 1 and 2:

    • Histologically documented metastatic or locally advanced, incurable solid malignancy.
    • At least one prior line of systemic therapy for metastatic or locally advanced disease.

  • Advanced Triple Negative Breast Cancer (Dose Expansion):

    • Histologically proven invasive breast carcinoma with triple-negative receptor status.
    • At least 1 but no more than 2 prior lines of chemotherapy for metastatic or locally advanced disease.

  • Advanced Hormone Receptor-Positive/Endocrine-Refractory Breast Cancer (Dose Expansion):

    • Histologically proven invasive breast carcinoma with hormone receptor+, HER2- status.
    • Only postmenopausal women are eligible. - Previously received at least 1 line of aromatase inhibitor ± cyclin dependent kinase 4 and 6 (CDK4/6) inhibitor therapy. Prior combination therapies of AI or selective estrogen receptor degrader (SERD [fulvestrant]) ± CDK 4/6 inhibitor or AI plus everolimus will be permitted. Up to 1 prior line of systemic chemotherapy for metastatic disease is allowed.

  • Advanced Metastatic Castration-Resistant Prostate Cancer (Dose Expansion):

    • Histologically or cytologically confirmed prostate adenocarcinoma or poorly differentiated carcinoma of the prostate.
    • Surgically or medically castrated, with testosterone levels of \< 50 ng/dL (\< 2.0 nM). If a patient is being treated with LHRH agonists, this therapy must have been initiated at least 4 weeks prior to treatment start and must be continued throughout the study.
    • Patients must have received ≥1 androgen receptor (AR) signaling inhibitors and had disease progression RECIST v1.1 after no more than 1 prior chemotherapy for mCRPC.

  • Advanced Platinum-Resistant Ovarian Cancer (Dose Expansion):

    • Histologically or cytologically confirmed diagnosis of metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer.
    • Platinum-resistant ovarian cancer defined as disease progression following a response within 180 days following the last administered dose of platinum therapy. Patients who have lack of response (SD) or disease progression while receiving the most recent platinum-based therapy are not eligible.
    • Received up to 3 lines of systemic therapy for platinum-sensitive disease, with the most recent regimen platinum-containing, and no prior systemic therapy for platinum-resistant or refractory disease.

  • General:

    • Tumor tissue for mandatory pre-treatment and on-treatment biopsies.
    • One or more tumors measurable on radiographic imaging defined by RECIST 1.1.
    • Adult patients ≥18 years of age.
    • ECOG performance status (PS) score of 0 or 1.
    • Life expectancy of at least 12 weeks.
    • Disease-free of active second/secondary or prior malignancies for ≥2 years, with the exception of currently treated basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix or breast.
    • Acceptable liver, renal, hematologic and coagulation function.

Exclusion criteria

Exclusion Criteria:

  • Hematologic malignancies or multiple myeloma.

  • For the Dose Expansion cohorts the following cancers are not permitted:

    • Any of the following pure histologies of ovarian cancer: germ cell, sex cord stroma, carcinosarcoma, or sarcoma.
    • Small cell or pure neuroendocrine prostate carcinoma that has not yet been treated with at least one line of platinum-based chemotherapy (prostate adenocarcinoma with immunohistochemical neuroendocrine differentiation but without histological small cell that is naïve to platinum-based chemotherapy will be allowed.)
    • Inflammatory breast cancer.
  • New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months, or unstable arrhythmia.

  • Cardiac function:

    • Known ejection fraction of \<50% by gated radionuclide study (e.g., multi-gated acquisition scan);
    • Fridericia-corrected QT interval (QTcF) >470 msec (female) or >450 msec (male), or history of congenital long QT syndrome;
    • Any ECG abnormality, including pericarditis, that in the Investigator's opinion, would preclude safe participation in the study.
  • Active, uncontrolled bacterial, viral, or fungal infections within 7 days of study entry requiring systemic therapy.
  • Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

  • Known clinically important respiratory impairment.

    • History of (non-infectious) pneumonitis that required steroids or current pneumonitis.
    • History of interstitial lung disease.
  • Clinically significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis.
  • Known to be human immunodeficiency virus (HIV) positive or have hepatitis B surface antigen (HBSAg) or hepatitis C antibodies (HCAb) unless hepatitis C virus (HCV) RNA is undetected/negative.
  • History of major organ transplant (i.e., heart, lungs, liver, and kidney).
  • History of an allogeneic bone marrow transplant.
  • History of an autologous bone marrow transplant within 90 days of study entry.
  • Symptomatic central nervous system (CNS) malignancy or metastasis. Patients with treated CNS metastases are eligible, provided their disease is radiographically stable, asymptomatic, and they are not currently receiving corticosteroids and/or anticonvulsants. Radiation must have been completed at least 14 days prior to study entry. Screening of asymptomatic patients without a history of CNS metastases is not required.
  • Serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.
  • Pregnant or nursing women.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    All Solid Tumors

    Phase 1b, Part 1 Dose Escalation: TRX518 + CTX Combination (28-Day Cycle): Subjects receive the following treatment: * Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle * Assigned dose of cyclophosphamide administered intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle Phase 1b, Part 2 Dose Escalation: TRX518 + CTX + avelumab in (28-Day Cycle): Subjects receive the following treatment: * Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle * Fixed dose of avelumab administered intravenously on D2 and D16 per cycle * Fixed dose of cyclophosphamide administered at the MTD from Part 1 intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle

    Drug: TRX518 · Drug: Cyclophosphamide · Drug: Avelumab

  • Experimental
    Advanced Triple Negative Breast Cancer

    Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle): Subjects receive the following treatment: * Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle * Fixed dose of avelumab administered intravenously on D2 and D16 per cycle * Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle

    Drug: TRX518 · Drug: Cyclophosphamide · Drug: Avelumab

  • Experimental
    Advanced Hormone Receptor+/Endocrine Refractory Breast Cancer

    Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle): Subjects receive the following treatment: * Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle * Fixed dose of avelumab administered intravenously on D2 and D16 per cycle * Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle

    Drug: TRX518 · Drug: Cyclophosphamide · Drug: Avelumab

  • Experimental
    Advanced Metastatic Castration-Resistant Prostate Cancer

    Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle): Subjects receive the following treatment: * Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle * Fixed dose of avelumab administered intravenously on D2 and D16 per cycle * Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle

    Drug: TRX518 · Drug: Cyclophosphamide · Drug: Avelumab

  • Experimental
    Advanced Platinum-Resistant Ovarian Cancer

    Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle): Subjects receive the following treatment: * Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle * Fixed dose of avelumab administered intravenously on D2 and D16 per cycle * Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle

    Drug: TRX518 · Drug: Cyclophosphamide · Drug: Avelumab

Interventions

  • DrugTRX518

    Administered by IV infusion

  • DrugCyclophosphamide

    Administered by IV infusion

  • DrugAvelumab

    Administered by IV infusion

    Also known as: BAVENCIO®

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of subjects with dose limiting toxicities which will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)

    Time frame: Baseline through 30 days post last dose (5 months)

  2. Phase 1b: Identify the recommended Phase 2 dose (RP2D) of CTX in combination with fixed doses of TRX518 ± avelumab

    Time frame: Baseline through end of Cycle 1 (Day 28)

  3. Phase 2a: Efficacy in Breast and Ovarian Cancer Groups: objective response rate

    To determine the objective response rate according to modified RECIST v1.1

    Time frame: Baseline to study completion (approximately 4 months)

  4. Phase 2a: Efficacy in Prostate Cancer Group: objective response rate

    To determine the objective response rate according to modified RECIST 1.1 and PCWG3 guidelines

    Time frame: Baseline to study completion (approximately 4 months)

Secondary outcomes

  1. To determine the objective disease control rate (ODCR) according to modified RECIST 1.1 in breast and ovarian cancer groups

    Time frame: Baseline to study completion (approximately 4 months)

  2. To determine the objective disease control rate (ODCR) according to modified RECIST 1.1 and PCWG3 guidelines in prostate cancer group

    Time frame: Baseline to study completion (approximately 4 months)

  3. To determine the duration of response according to modified RECIST 1.1 in breast and ovarian cancer groups

    Time frame: Baseline to study completion (approximately 4 months)

  4. To determine the duration of response according to modified RECIST 1.1 and PCWG criteria in prostate cancer group

    Time frame: Baseline to study completion (approximately 4 months)

  5. To determine the progression free survival according to RECIST 1.1 in breast and ovarian cancer groups

    Time frame: Baseline to study completion (approximately 4 months)

  6. To determine the progression free survival according to RECIST 1.1 and PCWG3 criteria in prostate cancer group

    Time frame: Baseline to study completion (approximately 4 months)

  7. To determine overall survival (OS) in all cancer groups

    Time frame: Baseline to study completion (approximately 4 months)

  8. To determine the PSA response in prostate cancer group

    Time frame: Baseline to study completion (approximately 4 months)

  9. Evaluate the effect of TRX518 in combination with cyclophosphamide and avelumab on lymphoid cell subset numbers and function

    Time frame: Various timepoints through study completion (approximately 4 months)

  10. Time to peak concentration (Tmax)

    Observations of the distribution, duration of effects and chemical changes of TRX518 and avelumab in the body and the effects and routes of the body's elimination of TRX518 and avelumab

    Time frame: Various timepoints through study completion (approximately 4 months)

  11. TRX518 and avelumab peak concentration (Cmax)

    Observations of the distribution, duration of effects and chemical changes of TRX518 and avelumab in the body and the effects and routes of the body's elimination of TRX518 and avelumab

    Time frame: Various timepoints through study completion (approximately 4 months)

  12. Area under the curve (AUC)

    Observations of the distribution, duration of effects and chemical changes of TRX518 and avelumab in the body and the effects and routes of the body's elimination of TRX518 and avelumab

    Time frame: Various timepoints through study completion (approximately 4 months)

  13. Assess TRX518 and avelumab immunogenicity

    Time frame: Various timepoints through study completion (approximately 4 months)

07

Study locations

4 sites
  • Horizon Oncology Research
    Lafayette, Indiana 47905, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03861403
Lead sponsor
Leap Therapeutics, Inc.
Collaborators
Pfizer, Merck KGaA, Darmstadt, Germany
Responsible party
Sponsor
First posted
Mar 4, 2019
Start date
May 20, 2019
Primary completion
Jul 14, 2020
Completion
Jul 14, 2020
Last update
Nov 30, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Breast Neoplasms→

Other studies from this sponsor

Leap Therapeutics, Inc.

Start the discussion